Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by Brown Advisory Securities LLC

Claudine Rigal
Juillet 20, 2017

However, higher operating expenses continue to be a woe. Cowen & Co maintained Edwards Lifesciences Corp (NYSE:EW) rating on Wednesday, April 27. Insiders sold 252,101 shares of company stock worth $28,141,680 over the last quarter. The stock of Edwards Lifesciences Corp (NYSE:EW) has "Sell" rating given on Wednesday, April 27 by Citigroup. The stock now has an average rating of "Buy" and a consensus target price of $116.99. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current fiscal year. We believe several recent FDA approvals received by the company including its SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting the investors' confidence over the stock. Financial Counselors Inc. now owns 13,637 shares of the medical research company's stock worth $1,283,000 after buying an additional 282 shares during the period. First Allied Advisory Services Inc. now owns 6,802 shares of the medical research company's stock worth $637,000 after buying an additional 4,531 shares during the last quarter. Laurel Grove Capital LLC purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth approximately $201,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at $126,959,000.

A number of other research firms have also recently commented on EW. Morgan Stanley now owns 1,485,058 shares of the medical research company's stock valued at $139,699,000 after buying an additional 332,671 shares during the period. Finally, Evercore ISI raised shares of Edwards Lifesciences Corporation from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $98.50 to $110.00 in a report on Monday, March 27th. The company has market cap of $9.64 billion. Institutional investors and hedge funds own 83.62% of the company's stock. BidaskClub lowered shares of Edwards Lifesciences Corporation from a "strong-buy" rating to a "buy" rating in a report on Tuesday, June 13th. The company's 50 day moving average is $115.58 and its 200-day moving average is $100.62. Brown Advisory Securities LLC's holdings in Edwards Lifesciences Corporation were worth $350,000 as of its most recent filing with the SEC.

5/16/2017-Goldman Sachs Group, Inc. After $1.52 actual earnings per share reported by Accenture Plc for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth. Canaccord Genuity reiterated a "buy" rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The business had revenue of $883.50 million for the quarter, compared to analyst estimates of $776.51 million. The firm's revenue was up 26.7% compared to the same quarter a year ago.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Alliancebernstein L.P. increased its position in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Tuesday, April 25th.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was copied illegally and republished in violation of U.S. and worldwide copyright and trademark laws. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/18/edwards-lifesciences-corporation-ew-shares-sold-by-roosevelt-investment-group-inc-updated-updated-updated.html. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock.

Shares of Edwards Lifesciences Corporation (EW) opened at 116.49 on Monday.

On 5/31/2017 Patrick B. Verguet, VP, sold 10,000 with an average share price of $114.88 per share and the total transaction amounting to $1,148,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

On 6/29/2017 Donald E. Bobo, Jr., VP, sold 5,600 with an average share price of $117.15 per share and the total transaction amounting to $656,040.00.

On 6/7/2017 Michael A. Mussallem, CEO, sold 32,900 with an average share price of $118.05 per share and the total transaction amounting to $3,883,845.00. The disclosure for this sale can be found here. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring.

The Business's Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Its segments include United States, Europe, Japan and Rest of World.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL